Alkermes (ALKS) Asset Writedowns and Impairment (2010 - 2026)
Alkermes (ALKS) posted quarterly Asset Writedowns and Impairment of $4.3 million for Q2 2026, up 44.16% year-over-year from $3.0 million in Q2 2025, and up 230.99% quarter-over-quarter from $1.3 million in Q1 2026.
Alkermes (ALKS) Asset Writedowns and Impairment (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Asset Writedowns and Impairment for 17 consecutive years, with $4.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Asset Writedowns and Impairment rose 44.16% year-over-year to $4.3 million; the TTM figure through Jun 2026 stood at $7.6 million (up 35.97% YoY), while the FY2025 annual figure was $5.3 million, up 17.71% from the prior year.
- Asset Writedowns and Impairment grew to $4.3 million in Q2 2026 per ALKS's latest filing, from $1.3 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $4.9 million in Q4 2023 and bottomed at -$282000.0 in Q4 2024.
- Historically, Asset Writedowns and Impairment has averaged $1.5 million across 5 years, with a median of $1.0 million in 2025.
- Annual changes were most pronounced in 2024 — Asset Writedowns and Impairment plunged 124.53% — and 2025, when it surged 3860.76%.
- Alkermes' Asset Writedowns and Impairment stood at $1.8 million in 2022, then jumped by 176.47% to $4.9 million in 2023, then plunged by 105.71% to -$282000.0 in 2024, then soared by 424.47% to $915000.0 in 2025, then jumped by 368.09% to $4.3 million in 2026.
- Business Quant data shows ALKS's Asset Writedowns and Impairment at $4.3 million in Q2 2026, $1.3 million in Q1 2026, and $915000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.28 Mn |
| Jun 30, 2026 | 4.28 Mn |
| Mar 31, 2026 | 1.29 Mn |
| Mar 31, 2026 | 1.29 Mn |
| Dec 31, 2025 | 915,000.00 |
| Dec 31, 2025 | 915,000.00 |
| Sep 30, 2025 | 1.15 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 2.97 Mn |
| Jun 30, 2025 | 2.97 Mn |
| Mar 31, 2025 | 274,000.00 |
| Mar 31, 2025 | 274,000.00 |
| Dec 31, 2024 | -282,000.00 |
| Dec 31, 2024 | -282,000.00 |
| Sep 30, 2024 | 2.66 Mn |
| Sep 30, 2024 | 2.66 Mn |
| Jun 30, 2024 | -79,000.00 |
| Jun 30, 2024 | -79,000.00 |
| Mar 31, 2024 | 2.22 Mn |
| Mar 31, 2024 | 2.22 Mn |